BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 29045831)

  • 1. USP7 Is a Tumor-Specific WNT Activator for APC-Mutated Colorectal Cancer by Mediating β-Catenin Deubiquitination.
    Novellasdemunt L; Foglizzo V; Cuadrado L; Antas P; Kucharska A; Encheva V; Snijders AP; Li VSW
    Cell Rep; 2017 Oct; 21(3):612-627. PubMed ID: 29045831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. USP7 inactivation suppresses APC-mutant intestinal hyperproliferation and tumor development.
    Novellasdemunt L; Kucharska A; Baulies A; Hutton C; Vlachogiannis G; Repana D; Rowan A; Suárez-Bonnet A; Ciccarelli F; Valeri N; Li VSW
    Stem Cell Reports; 2023 Feb; 18(2):570-584. PubMed ID: 36669491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parthenolide inhibits ubiquitin-specific peptidase 7 (USP7), Wnt signaling, and colorectal cancer cell growth.
    Li X; Kong L; Yang Q; Duan A; Ju X; Cai B; Chen L; An T; Li Y
    J Biol Chem; 2020 Mar; 295(11):3576-3589. PubMed ID: 32029476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. USP7 inhibitor P5091 inhibits Wnt signaling and colorectal tumor growth.
    An T; Gong Y; Li X; Kong L; Ma P; Gong L; Zhu H; Yu C; Liu J; Zhou H; Mao B; Li Y
    Biochem Pharmacol; 2017 May; 131():29-39. PubMed ID: 28216017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. USP7 inhibits Wnt/β-catenin signaling through promoting stabilization of Axin.
    Ji L; Lu B; Zamponi R; Charlat O; Aversa R; Yang Z; Sigoillot F; Zhu X; Hu T; Reece-Hoyes JS; Russ C; Michaud G; Tchorz JS; Jiang X; Cong F
    Nat Commun; 2019 Sep; 10(1):4184. PubMed ID: 31519875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of the 15 amino acid repeats of truncated APC to beta-catenin degradation and selection of APC mutations in colorectal tumours from FAP patients.
    Kohler EM; Brauburger K; Behrens J; Schneikert J
    Oncogene; 2010 Mar; 29(11):1663-71. PubMed ID: 19966865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. YAP-dependent ubiquitination and degradation of β-catenin mediates inhibition of Wnt signalling induced by Physalin F in colorectal cancer.
    Chen C; Zhu D; Zhang H; Han C; Xue G; Zhu T; Luo J; Kong L
    Cell Death Dis; 2018 May; 9(6):591. PubMed ID: 29789528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic mutations in adenomatous polyposis coli (Apc) activate mechanistic target of rapamycin complex 1 (mTORC1) in mice and zebrafish.
    Valvezan AJ; Huang J; Lengner CJ; Pack M; Klein PS
    Dis Model Mech; 2014 Jan; 7(1):63-71. PubMed ID: 24092877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RK-287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model.
    Mizutani A; Yashiroda Y; Muramatsu Y; Yoshida H; Chikada T; Tsumura T; Okue M; Shirai F; Fukami T; Yoshida M; Seimiya H
    Cancer Sci; 2018 Dec; 109(12):4003-4014. PubMed ID: 30238564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A common role for various human truncated adenomatous polyposis coli isoforms in the control of beta-catenin activity and cell proliferation.
    Chandra SH; Wacker I; Appelt UK; Behrens J; Schneikert J
    PLoS One; 2012; 7(4):e34479. PubMed ID: 22509309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scutellaria barbata D. Don inhibits colorectal cancer growth via suppression of Wnt/β-catenin signaling pathway.
    Wei LH; Lin JM; Chu JF; Chen HW; Li QY; Peng J
    Chin J Integr Med; 2017 Nov; 23(11):858-863. PubMed ID: 29080197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance of adenomatous polyposis coli (APC)-mutant colorectal cancer is dependent on Wnt/beta-catenin signaling.
    Scholer-Dahirel A; Schlabach MR; Loo A; Bagdasarian L; Meyer R; Guo R; Woolfenden S; Yu KK; Markovits J; Killary K; Sonkin D; Yao YM; Warmuth M; Sellers WR; Schlegel R; Stegmeier F; Mosher RE; McLaughlin ME
    Proc Natl Acad Sci U S A; 2011 Oct; 108(41):17135-40. PubMed ID: 21949247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenomatous polyposis coli (APC) membrane recruitment 3, a member of the APC membrane recruitment family of APC-binding proteins, is a positive regulator of Wnt-β-catenin signalling.
    Brauburger K; Akyildiz S; Ruppert JG; Graeb M; Bernkopf DB; Hadjihannas MV; Behrens J
    FEBS J; 2014 Feb; 281(3):787-801. PubMed ID: 24251807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. APC is essential for targeting phosphorylated beta-catenin to the SCFbeta-TrCP ubiquitin ligase.
    Su Y; Fu C; Ishikawa S; Stella A; Kojima M; Shitoh K; Schreiber EM; Day BW; Liu B
    Mol Cell; 2008 Dec; 32(5):652-61. PubMed ID: 19061640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. α-Catenin interacts with APC to regulate β-catenin proteolysis and transcriptional repression of Wnt target genes.
    Choi SH; Estarás C; Moresco JJ; Yates JR; Jones KA
    Genes Dev; 2013 Nov; 27(22):2473-88. PubMed ID: 24240237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-catenin degradation mediated by the CID domain of APC provides a model for the selection of APC mutations in colorectal, desmoid and duodenal tumours.
    Kohler EM; Chandra SH; Behrens J; Schneikert J
    Hum Mol Genet; 2009 Jan; 18(2):213-26. PubMed ID: 18854359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Smad4-mediated signaling inhibits intestinal neoplasia by inhibiting expression of β-catenin.
    Freeman TJ; Smith JJ; Chen X; Washington MK; Roland JT; Means AL; Eschrich SA; Yeatman TJ; Deane NG; Beauchamp RD
    Gastroenterology; 2012 Mar; 142(3):562-571.e2. PubMed ID: 22115830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ubiquitin ligase RNF220 enhances canonical Wnt signaling through USP7-mediated deubiquitination of β-catenin.
    Ma P; Yang X; Kong Q; Li C; Yang S; Li Y; Mao B
    Mol Cell Biol; 2014 Dec; 34(23):4355-66. PubMed ID: 25266658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-155 Is Downregulated in Familial Adenomatous Polyposis and Modulates WNT Signaling by Targeting AXIN1 and TCF4.
    Prossomariti A; Piazzi G; D'Angelo L; Miccoli S; Turchetti D; Alquati C; Montagna C; Bazzoli F; Ricciardiello L
    Mol Cancer Res; 2018 Dec; 16(12):1965-1976. PubMed ID: 30072583
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Tanaka N; Mashima T; Mizutani A; Sato A; Aoyama A; Gong B; Yoshida H; Muramatsu Y; Nakata K; Matsuura M; Katayama R; Nagayama S; Fujita N; Sugimoto Y; Seimiya H
    Mol Cancer Ther; 2017 Apr; 16(4):752-762. PubMed ID: 28179481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.